## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($61.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. DXCM DEADLINE: DexCom, Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Looming Deadline in Lawsuit**
- Source: FOX40 News | 20251210T010925 | Neutral | Relevance: 100%
-  Investors in DexCom, Inc. (NASDAQ:DXCM) are urged to contact Kirby McInerney LLP regarding a securities fraud class action lawsuit, with a lead plaintiff deadline of December 26, 2025. The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitors, leading to inaccurate readings, health risks, and a decline in stock prices due to regulatory scrutiny and downgrades. The firm is seeking to represent investors who suffered losses during the period of January 8, 2024, through September 17, 2025.

**2. Did You Lose Money on DexCom, Inc. (DXCM)? Levi & Korsinsky Urges Investors to Act Before December 26, 2025**
- Source: CBS 42 | 20251207T000830 | Neutral | Relevance: 99%
-  Levi & Korsinsky LLP has filed a class action securities lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who suffered losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and presenting health risks, thereby leading to materially false or misleading public statements. Investors are urged to contact the firm by December 26, 2025, to learn about their potential recovery options.

**3. Lost Money on DexCom, Inc. (DXCM)? Contact Levi & Korsinsky to Join Class Action Before December 26, 2025**
- Source: FOX40 News | 20251207T160836 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP has filed a class action securities lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of shareholders who experienced losses between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which the company allegedly concealed. Shareholders affected by these alleged misrepresentations are encouraged to contact Levi & Korsinsky to learn about their rights to potential recovery.

**4. DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!**
- Source: CBS 42 | 20251207T120803 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) for alleged violations of federal securities laws. The lawsuit claims DexCom made misleading statements regarding unauthorized design changes to its G6 and G7 devices, which reportedly rendered them less reliable and posed health risks. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, are encouraged to join the lawsuit, with a deadline of December 26, 2025, to request to be appointed lead plaintiff.

**5. Class Action by Pomerantz LLP Filed Against DexCom, Inc. – DXCM**
- Source: WLNS 6 News | 20251208T070000 | Neutral | Relevance: 99%
- Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. (DXCM) and certain officers, alleging misleading statements about the company's continuous glucose monitoring (CGM) systems, specifically the G6 and G7. The lawsuit claims that DexCom made material design changes to these devices without FDA authorization, rendering them less reliable and posing health risks to users. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, have until December 26, 2025, to seek appointment as Lead Plaintiff.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |
| 2025-11-10 | Morgan Stanley | $63 | $89 | -29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |
| 2025-11-10 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 11.3% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.0B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 26.7 |
| Current P/E | 32.1 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 2.3% (minimal 5-day change). Below STRENGTH zone by 0.7pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Outperforming sector by 6.9pp, stock-specific strength. Below SMA200 (0.89x), long-term trend not supportive. MACD histogram positive (0.86), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.34% (CS: 79) | Neutral |
| RSI_14 | 61.8 | Neutral |
| MACD Histogram | 0.86 | Bullish |
| vs SMA20 | 1.072x | Above |
| vs SMA50 | 1.036x | Above |
| vs SMA200 | 0.887x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $66.33
- **Stop Loss:** $61.97 (6.6% risk)
- **Target:** $70.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 68
- **Position Value:** $4,510.44
- **Portfolio %:** 4.51%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*